TEL AVIV, ISRAEL AND RALEIGH, NC

Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib’s potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) and for antitumor radiotherapy As an oral, small molecule pill that is highly stable with a more than five-year […]

RedHill received the first tranche of $5 million in a private placement of restricted stock priced at $6.04 per ADS, representing a 20% premium based on the 30 trading days’ volume weighted average price (VWAP) ending on the effective date RedHill granted Kukbo a right of first offer for opaganib, RHB-107 (upamostat) and Talicia® for South Korea […]

Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date    Opaganib’s unique, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is expected to maintain effect against other emerging variants The global 475-patient Phase 2/3 […]

Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstrated potent inhibition of Beta and Gamma variants and is expected to be effective against emerging variants, including Delta and Delta Plus RedHill […]